In an effort to provide women with an innovative and accessible treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles, Pelvital has raised $2.68M in seed funding for its novel product, Flyte. The round was led by Boomerang Ventures. Other participants include VisionTech Partners, Wisconsin Investment Partners, and Edward Bergmark, PhD, the Founder and former CEO of Optum.
Flyte is an FDA-approved, at-home intravaginal device, that delivers mechanotherapy, a proven treatment modality that rapidly and effectively strengthens pelvic floor muscles. Flyte was brought to life through a collaboration between physicians from the Arctic University of Norway and experts in gynecology, muscle rehabilitation, and urinary incontinence treatments. Two clinical trials studied the safety, efficacy, and durability of Flyte in women with SUI. These studies demonstrated that Flyte delivers continence rates and durability comparable to surgery, yet with a conservative, fast, and convenient treatment.
Lydia Zeller, President and CEO of Pelvital, shared: “Pelvital is committed to empowering both women and clinicians with transformative products backed by strong clinical evidence. We are excited to partner with Boomerang as we execute on our vision to be the gold standard of care for treatment of urinary incontinence, an issue that impacts one in two women. Boomerang’s focus on transformative healthcare technology is a perfect match as we introduce our next generation product to the clinical community. In the context of significant gaps in health equity – and in particular for issues that disproportionately impact peri-menopausal and menopausal women – increasing access to clinically proven, patient-centric treatments is vitally important.”
Source: FemTech Insider
